Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd
Danish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx […]
Anacura aquires Ohmx.bio
Merger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services.
Ten drug recommendations by EMA
EMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting.
Consortium led by Evotec enters obesity drug space
Drug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases.<br […]
Semarion Ltd. wins Ignite SME award at SLAS Europe
UK-based Semarion Ltd. was honoured as the most innovative company in the field of laboratory automation at SLAS Europe 2024 in Barcelona. <br /><br /><br />
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
US pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones. <div></div>
SLAS Europe 2024 honours products with most impact
Swiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector.
Hornet Therapeutics reports first data of EBV-triggered disease blocker
Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.
AstraZeneca puts step into lucrative obesity market
Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.